Last reviewed · How we verify
Yangzhengxiaoji capsule combined with CHOP regimen
Yangzhengxiaoji capsule combined with CHOP regimen is a Small molecule drug developed by Mingzhi Zhang. It is currently FDA-approved.
Yangzhengxiaoji capsule, combined with the CHOP regimen, is a marketed treatment developed by Mingzhi Zhang. The key composition patent is set to expire in 2028, providing a clear period of exclusivity. The primary risk is the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market adoption.
At a glance
| Generic name | Yangzhengxiaoji capsule combined with CHOP regimen |
|---|---|
| Sponsor | Mingzhi Zhang |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Yangzhengxiaoji capsule combined with CHOP regimen CI brief — competitive landscape report
- Yangzhengxiaoji capsule combined with CHOP regimen updates RSS · CI watch RSS
- Mingzhi Zhang portfolio CI